Objective: To comprehensively review the available evidence and existing consensus reports and guidelines regarding the pregnancy and reproductive implications of the mosquito transmitted Zika virus infection. A primary focus was to provide pertinent information to aid clinicians in the management of pregnancies at risk for, exposed to or with confirmed Zika virus infection (ZIV).
landscape that has so far characterized this outbreak.
Introduction
An epidemiological alert was issued by the Pan American Health Organization/World Health Organization (PAHO/WHO) on November 2015 due to an unusually large increase in the reported cases of microcephaly [1] . As of November (2015) the frequency of microcephaly reported in Brazil increased to 99.7 cases/100,000 live births compared to a rate of 5.7/100,000 live births in 2010 [2] . This increase coincided with the Zika virus (ZIKV) infection outbreak in Pernambuco, a northeastern State of Brazil [1] . As of November (2015) the number of reported microcephaly cases in Pernambuco had increased from an average of 10 per year to 141 cases from January to mid-November of 2015 [1] . Between October 2015 and January 2016 approximately 4,180 suspected cases of microcephaly have been reported in Brazil of which 270 have currently been confirmed [2, 3] . Six of the 270 cases were found to be associated with the ZIKV [2, 3] . Grave concerns have thus been raised regarding a potential association between ZIKV and microcephaly. Autochthonous (arising from the area) transmission has now been reported in 19 countries in the Americas in addition to Brazil [4] . Pregnancy data are urgently needed to answer questions such as the fetal risks, the rates of newborn transmission, and the risk associated with breastfeeding.
The aim of our review is to inform obstetric care providers about the potential implications of ZIKV exposure in pregnancy and present management strategies based on the current literature and guidelines, including algorithms from the Center for Disease Control and 
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ZIKV: Epidemiology -Incidence and Geographic Trail
A member of the family Flaviviridae, genus Flavivirus, ZIKV is a single stranded RNA arbovirus that uses a mosquito as a vector to transmit the disease [5, 6, 7] . In 1947-48 the virus was detected in the arboreal mosquito of the Aedes genus within the Zika forest in Uganda [6, 7, 8] . Once thought to be sylvatic (affecting only wild or peri-domestic animals), ZIKV was first isolated in rhesus monkeys in 1947 by a yellow fever surveillance network in the Zika forest [6, 7, 8, 9] . Anti-Zika antibodies have been detected in non-human primates and large mammals (orangutan, zebras, elephants, etc.) including rodents in Pakistan. However, the definitive reservoir i.e. the long term host, remains unknown [10] . Antibodies were first identified in humans in Nigeria in 1954 [11] . Since that time the ZIKV has spread from Uganda to Nigeria and to countries in West Africa, and in addition has spread from Uganda to Malaysia, Micronesia, French Polynesia and the Cape Verde islands [8] . The ZIKV has now been isolated in mosquitoes and humans in Indonesia, Philippines, India, Thailand and Europe and from different mosquito species within the Aedes genus [8] . Prior to 2007, primates and large mammals served as the main hosts of ZIKV [7] . Documented human ZIKV exposures occurred sporadically in central and western Africa, Pakistan and South Asia, with only 14 human cases reported prior to 2007 [8] .
The ZIKV is related to other flaviviruses namely: dengue, West Nile virus, yellow fever, and Japanese encephalitis virus [9] . The clinical symptoms of ZIKV can be similar yet milder than dengue infection and may have been confused for or occurred concurrently with dengue outbreaks in the past [5, 8, 12] . N-linked glycosylation on the E protein of the ZIKV enhances infectivity. It has been hypothesized that changes in N-linked glycosylation site could potentially affect ZIKV transmission and the development of complications such as Gillian-Barre syndrome (GBS) and fetal brain anomalies [8, 9, 12] . Further studies are required to resolve this question.
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The first documented ZIKV epidemic among humans occurred in the Yap State of Micronesia in 2007 [5, 9, 12, 13, 14] . Clinical symptoms included rash, arthralgia and conjunctivitis and cases were initially misidentified as dengue based on rapid laboratory assay [13] . Further testing using reverse transcriptase-polymerase chain reaction (RT-PCR) technique ultimately identified ZIKV ribonucleic acid (RNA) [5, 13] . In 2014, another ZIKV outbreak occurred in the Pacific Islands. Cook Island had 50 confirmed cases, New Caledonia had 35 imported confirmed cases, and 1,365 confirmed autochthonous cases. French Polynesia had 383 confirmed cases, and an autochthonous case was reported on Easter Island, in Chile [12, 14] .
In May 2015, the first autochthonous case was confirmed in Brazil and spread to 15 states by November 2015 [15, 16] .
-From October-November 2015 additional autochthonous cases were reported in Columbia, Paraguay, Suriname, Venezuela, El Salvador, Guatemala and Mexico [16, 17] . The first case of ZIKV infection acquired in the United States was identified in Texas, January 2016, and is currently undergoing investigation [18] . Texas Health Department officials reported that the infection was likely sexually transmitted from a partner who had recently traveled to Venezuela where he became ill and tested positive for ZIKV. [18, 19] .
Currently there are important unanswered questions regarding the pathogenesis of ZIKV:
reservoirs, modes of transmission, the frequency of and the full spectrum of clinical presentation in human infection, and possible complications. Further, uncertainties remain as to the outcome of coinfection with other arboviruses such as the dengue virus.
ZIKV Transmission
The Aedes mosquito ingests the virus while feeding on an infected animal or human host.
The mosquito harbors the virus without harm to itself and subsequently transmits it during the act of feeding on another victim [14] . Aedes mosquitoes actively feed from dawn until dusk but may do so at any time during the day and night [14] . It is a sequential feeder, ingesting a small amount of blood at a time and thus increasing the number of potential victims.
ZIKV has been detected in semen, and sexual transmission now appears to have been potentially responsible for two cases of non-vector borne infection of sexual partners [18, 19, 20] .
In Tahiti in 2013, a male patient reported two illnesses consistent with ZIKV infection, with the first having occurred 8 weeks prior to the second infection [21] . Two weeks post resolution of clinical symptoms from the second reported infection he experienced hematospermia. A medical exam confirmed the diagnosis of hematospermia, and a questionnaire ruled out other potential causes. His semen, urine and blood were tested using RT-PCR -the blood and urine specimens were negative for ZIKV RNA while the semen specimen was positive for ZIKV RNA [21] . The duration after clinical infection in which the ZIKV can be isolated from the semen is currently unknown [21] Please refer to the section within this article labeled "Prevention of Sexual
Transmission" for information on recommendations to reduce the risk of transmitting ZIKV during sexual activity.
During the New Caledonian ZIKV epidemic (2014), urine from six patients (gender not recorded) was tested for ZIKV by RT-PCR. Urine from two of the six patients tested positive for ZIKV RNA, with one test remaining positive for >20 days after serum ZIKV RNA became undetectable [22] . Further, transmission via a blood transfusion has not been documented [23] .
However three percent of asymptomatic blood donors in French Polynesia were found to be
positive for ZIKV based on RT-PCR testing, thus transmission via this route appears plausible [23] .
Perinatal Transmission
Concerns regarding transplacental transmission of ZIKV from mother to fetus have increased as reports of the potential association between maternal ZIKV exposure and fetal/newborn congenital microcephaly and other brain anomalies have surfaced [1, 2, 3, 16] .
Vertical transmission of ZIKV can potentially occur transplacentally or during labor and delivery 
Clinical Symptoms
The ZIKV incubation period ranges from 3-12 days after the mosquito bite [14, 16] . The illness is usually mild and resolves within two to seven days [14, 16] . The clinical manifestations of an infection , should they develop, may include acute onset mild fever (<38.5℃) , mild-moderate arthralgia (notably of the small joints of hands and feet), non-purulent conjunctivitis or conjunctival hyperemia, maculopapular rashes usually spreading downward from the face to the limbs and frequently pruritic, and nonspecific symptoms such as headaches, myalgia, and asthenia [14, 16] . It is estimated that only 18% of individuals infected with ZIKV become symptomatic [17] .
In . It has been hypothesized that the increase in GBS cases may be due to an evolution of the virus to a more virulent form or to an immunologic deficiency, and /or the result of simultaneous dengue and ZIKV infection [14, 25] .
Pregnant women who have a ZIKV infection experience symptoms concordant with the rate observed in the general population [17] . ZIKV is similar to other flaviviruses such as yellow fever and dengue and the arbovirus chikungunya and contribute to laboratory diagnostic difficulties due to the cross reactivity of these antibodies [17, 27] . It should be borne in mind that microcephaly is a complex disorder and may be acquired or congenital [33] . Congenital microcephaly may be genetic or associated with teratogens, brain injury, hypoxic-ischemic lesions, and trans-placental infections such as syphilis, toxoplasmosis,
rubella, cytomegalovirus and herpes simplex virus (STORCH infections) [17] . The WHO defines microcephaly as a head circumference ≤ 2 standard deviations below the mean for age and sex [17] . If the head circumference is >3 standard deviations (SD) below the mean on prenatal US biometry there is a 70% chance of the newborn having an intellectual disability [34] .
Microcephaly is difficult to detect prior to 28 weeks gestation [35] . This should be borne in mind in order to avoid giving premature assurance to the pregnant woman after an early apparently normal ultrasound is performed. Similarly, negative maternal symptomatology and history does not preclude the possibility of a congenital ZIKV infection. Viral testing, while imperative, is also not definitive. Further, given the complex etiology of microcephaly, evaluation for other potential causes including other infectious agents may be appropriate as dictated by clinical judgment. All of the above greatly complicates prenatal screening, counseling and management during pregnancy particularly in ZIKV epidemic regions. Important unanswered questions include the relationship of the trimester of onset of maternal infection with the frequency, severity and range of abnormalities that develop in the fetus and newborn .
Diagnosis & Management in Pregnancy
RT-PCR testing is recommended for ZIKV during the first week after the onset of maternal symptoms. Particularly in endemic regions, Plaque-reduction neutralization testing (PRNT) can be performed to measure virus specific neutralizing antibodies in order to differentiate between cross reacting antibodies in primary flavivirus infections, e.g., concomitant dengue virus and ZIKV infections, or a secondary flavivirus infection [36] . Neutralizing antibodies may still yield cross-reactive results in persons who were previously infected with another flavivirus, or have been vaccinated against yellow fever or Japanese encephalitis [4] .
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Infection with ZIKV may occur in any trimester. As previously stated the incubation period for a Zika virus infection ranges from 3-12 days after the bite of an infected mosquito. Zika virus IgM can be identified in serum as early as four days after the onset of clinical symptoms and may persist for up to 12 weeks [35] . A negative ZIKV screen may result if the RT-PCR was performed beyond the acute phase of the infection i.e. the first seven days of illness [35, 36] .
Further, a negative RT-PCR can still result even if testing is performed 5-7 days after symptom onset and serologic testing along with PRNT testing is advised [35, 36] . All positive Zika, dengue
and chikungunya viral testing results must be reported to the CDC [36] . It is worth reemphasizing that the fact that most individuals who contract a ZIKV infection remain asymptomatic, coupled with the need for complex viral testing procedures and interpretation, this renders diagnosis of ZIKV infection difficult and at times inconclusive.
The algorithm in Table 1 serves as a convenient tool and guide for the management of pregnant women with possible ZIKV exposure. Detailed information to assist the obstetric health care provider in interpreting laboratory findings is included in Table 1 Obstetrics and Gynecology (ACOG) [35, 37] . All pregnant women should be queried about recent travel, including recent travel of a male sexual partner during the current pregnancy, in order to ascertain potential exposure to ZIKV. There is currently no evidence that a previous ZIKV infection increases the risks for congenital birth defects in subsequent pregnancies [37] .
(Insert Table 1 )
Ultrasound Evaluation in Suspected or Confirmed Maternal Infection: A Suggested Approach
The CDC, Society for Maternal Fetal Medicine, and the American Congress of Obstetrics and Gynecology have all recommended ultrasounds in order to carefully evaluate the fetal brain and screen for other fetal anomalies in pregnant women who have been exposed to ZIKV, regardless of clinical symptoms or laboratory testing results [35, 37] . Serial US is recommended to detect microcephaly, intracranial calcifications or other fetal anomalies [35, 37] . It bears repeating that reduced brain growth can be associated with or occur in conditions with: 1) other fetal anomalies such as congenital heart disease (CHD), 2) toxoplasmosis, cytomegalovirus, herpes, syphilis, and rubella, 3) West Nile encephalitis virus -a flavivirus, 4) exposure to toxins, 5) consumption of teratogens, 6) malnutrition or metabolic disorders, or 7) genetic risk factors [31, 38] . These conditions should therefore be considered particularly when microcephaly is suspected in non-epidemic areas and as dictated by clinical judgment may be considered in the work up of suspected ZIKV-related microcephaly.
While a targeted fetal US exam has been recommended, at this time there are no detailed guidelines outlining the full content of such an exam in fetuses at risk for congenital ZIKV infection. The US evaluation should however address the type of anomalies that have so far been reported in existing case reports. We are suggesting an approach based on the findings in these reports. Most importantly, it is hoped that at this stage a prospective, uniform and systematic approach to ultrasound evaluation will generate data to establish the diagnostic accuracy of ultrasound assessment detecting fetal abnormalities and to guide future recommendations.
Biometry of the head, including head circumference measurements, should be performed to assess for microcephaly. Brain atrophy also involving the frontal lobes has been reported in congenital ZIKV [31] . The measurement of frontal-thalamic distance in the fetus has been used for the detection of frontal lobe hypoplasia in the mid-trimester fetus and could be considered J U S T A C C E P T E D [39] . Lateral ventricular measurement of both ventricles will be useful in the assessment for unilateral ventriculomegaly [38] . Trans-cerebellar diameter measurement should also be performed at each assessment for the detection of cerebellar hypoplasia, a reported finding in congenital ZIKV. Routine measurement of the cisterna magna will also provide information on cerebellar hypoplasia and enlarged cisterna magna both of which are reported to occur in these cases. Finally, increased scalp redundancy as a result of reduced head growth has also been noted in these newborns. Mid-trimester nuchal thickness measurement frequently used for Down syndrome risk assessment may be of value in identifying this scalp redundancy. In addition, qualitative evaluation should in addition be performed to detect brain calcifications (particularly around the lateral and fourth ventricles) but also in the frontal lobes and cerebellum and indeed the entire brain. Abnormal cerebral gyral patterns, hypoplasia of the thalami and brain stem, cataract, micro-ophthalmia and calcifications in the eye have been reported. Currently the timing of manifestation of these abnormalities on prenatal ultrasound is not known. The question as to how frequently prenatal US should be performed and more problematically when US surveillance should cease in the presence of apparently normal US scans are important but cannot currently be definitively answered given the lack of data. The authors are of the opinion however that for confirmed or strongly suspected maternal infection, given the availability and relatively low cost of ultrasound, follow up US exams for head growth and detection of intracranial anomalies may be justifiable for the duration of the pregnancy.
Ultrasound is useful for assessing brain calcifications which appear at this point to be an important feature of congenital ZIKV infection. Placental calcification has also been reported so 
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therefore be strongly considered in appropriate circumstances such as confirmed or strongly suspicious cases of ZIKV or in fetuses with positive or suspected cranial abnormalities on prenatal ultrasound. There are no known adverse effects of MRI to the fetus, and there does not appear to be significant negative longterm effects [40] . Cost and availability are very relevant considerations in determining the frequency of use of both US and MRI, even in well-resourced countries such as the USA. This is particularly the case for MRI. Availability and economic considerations should be factored in and will affect the feasibility of MRI use in different localities.
Symptom Management in Pregnancy
Recommendations for clinical symptom management are presented in Table 3 as a practical tool to be used in the clinical setting. Treatment of the clinical symptoms associated with ZIKV infection is largely supportive. Included are recommendations on symptom relief measures that are safe in pregnancy. While aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are not generally used in pregnancy, these medications should specifically be avoided until dengue infection is ruled out to reduce the risk of hemorrhage [17, 35] .
(Insert Table 3 )
Management of Postpartum Issues: Breastfeeding and Newborn Congenital ZIKV Infection Screening
Even though small amounts of ZIKV have been isolated in breast milk, the benefits of breastfeeding outweigh any short term neonatal risks [17, 24, 37, 41] . No definitive data exists in the published literature on oral transmission of ZIKV virus through breastfeeding. Thus ZIKV infection is not considered a deterrent to breastfeeding. [42] . It is important to note that the specificity and sensitivity for RT-PCR in amniotic fluid is unknown [35] . All positive postpartum newborn and maternal Zika and dengue virus results are to be reported to the CDC [36] . All newborns diagnosed with microcephaly or intracranial calcifications should have periodic evaluations by specialists for long term sequelae associated with this diagnosis. Parents should be informed of appropriate agencies offering social service assistance and counseling and other support services for children with microcephaly and other brain anomalies,.
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Prevention: Environmental and Personal Measures, Avoiding Travel to Active ZIKV Transmission Areas
In the absence of an available vaccine, developing other prevention strategies is key [14] .
It is estimated that it could take approximately 18 months to develop a ZIKV vaccine. Prevention of ZIKV infection encompasses environmental and personal measures [17, 43, 44] . Shown in Table 4 are outlines environmental and personal prevention measures to reduce ZIKV infection exposure. Up to date travel notices posted by the CDC can be found at http://wwwnc.cdc.gov/travel/notices. [45] . This includes travel advisories for countries where active transmission of the ZIKV is occurring. This advisory is labeled with an "Alert Level 2, Practice Enhanced Precautions" [45] . The website lists countries with active ZIKV transmission, along with specific information on prevention measures, and advises postponing travel for pregnant women, along with measures to reduce sexual transmission.
(Insert Table 4 )
Prevention of Sexual Transmission
Sexual transmission of the ZIKV is a non-vector-borne method of transmission [20, 21] .
Sexual transmission does appear to be a plausible risk in men harboring the ZIKV in their semen after infection due to a mosquito bite [18, 19, 20, 21] . intercourse with symptomatic male partners who had recently traveled to areas with ongoing ZIKV infections [46] . Despite being no longer detectable in blood, ZIKV was detected in semen at 62 days after onset of febrile disease . The virus however could not be cultured from semen [47] . One study reported that at greater than two weeks from onset of symptoms, the viral load in semen may be higher than that in blood or urine by a factor of 100,000 times [48] . This finding suggests that the ZIKV can continue to replicate in semen regardless of viremic status. assessing transmission risk is unpredictable and of questionable value at this time and so has not been recommended [21, 49] . This information is also provided in Table 4 for ease of use in a clinical setting. Table 4 ). Several South American and Caribbean governments have advised women to postpone pregnancy altogether during ZIKV epidemic [17] .
Biosafety
The CDC has established biosafety levels (BSL) as a means of identifying hazards of biological agents and appropriate environmental protection and personnel protection equipment required upon handling of such agents [50] . Levels range from 1 to 4, with BSL 4 involving the greatest risk and requiring the highest level of safety precautions. Zika and dengue viruses are classified as BSL 2 and are considered a moderate hazard to the environment and to personnel working with these pathogens. Chikungunya is classified as BSL 3 which includes pathogens or agents that may cause a lethal disease if inhaled [36, 50] . Handling of these infectious pathogens must follow specific guidelines that include standard and specialized microbiological procedures, laboratories where such specimens are tested.
Recent Update
In mid February 2016 the CDC received reports on 9 pregnant women in the United States who had traveled to ZIKV infected areas during their pregnancy. The ZIKV disease was confirmed via laboratory evaluation in all 9 of the pregnant women [51] . The outcomes among the 9 pregnancies are as follows: 2 early pregnancy losses, 2 elective terminations (one reportedly had a fetal ultrasound evaluation noting absence of corpus callosum, ventrigulomegaly and the MRI noted severe brain atrophy), 2 pregnancies are continuing without known complications, 2 delivered healthy infants, and 1 delivered at 39 weeks with severe microcephly (case in Hawaii) [51, 52] . Accelerated work on vaccine development is a clear priority. While the burden should not be placed exclusively on women of childbearing age, the risks and prevention strategies need to be communicated to them in an effective manner. Family planning is a critical tool that should be discussed with at risk individuals and families. Health care providers and agencies must work vigorously to inform the most vulnerable population -pregnant women and women of childbearing age -of the risks ZIKV poses to the fetus/newborn while minimizing alarm and panic.
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Assessment for brain atrophy involving frontal lobes
• Frontal-thalamic distance in the fetus has been used for the detection of frontal lobe hypoplasia in the mid-trimester fetus and could be considered.
• Lateral ventricular measurement of both ventricles will be useful in the assessment for unilateral ventriculomegaly [38] .
• Trans-cerebellar diameter measurement should also be performed at each assessment for the detection of cerebellar hypoplasia, a reported finding in congenital ZIKV.
• Routine measurement of the cisterna magna will also provide information on cerebral hypoplasia and enlarged cisterna magna in these cases.
• Increased scalp redundancy as a result of reduced head growth has been reported. Midtrimester nuchal thickness measurement frequently used for Down syndrome risk assessment may be of value in identifying this scalp redundancy in the mid-trimester.
Evaluation to detect brain calcifications. Evaluate the entire brain.
• 
Evaluate to detect placental calcifications
Overall fetal growth should be assessed
• Assess limb posture and movement • Clubbing of the foot should be assessed (given a report of arthrogryposis, hypertonia and spasticity in newborns [32] • Assess brainstem for abnormalities
• Assess for potential fetal consequences of difficulty swallowing: polyhydramnios and absent or reduced stomach bubble [35] . However, the best currently available data indicate that over 25% of congenital infection cases do not have microcephaly, likewise over 25% of congenital cases do not have brain calcifications-thus negative findings on US screening DO NOT guarantee an unaffected fetus [32] . †Prenatal US exam, particularly that performed earlier in pregnancy, is less sensitive for microcephaly than newborn measurements used to assess the cases referenced above ‡Positive US findings may only manifest or be appreciated after serial examinations and later in the pregnancy. These observations argue in favor of serial US evaluations in those determined to be at high enough risk based on laboratory, history or epidemiologic factors.
Updated 022116 • Pain:Mild to moderate arthralgia (small joints of hands and feet), myalgia (muscle pain): Acetaminophen (325 mg tabs) 650 mg every 4-6 hours, not to exceed 4000 mg/day. Avoid use of -ASA, NSAIDs †
• Asthenia (abnormal weakness, lack of energy). Promote rest.
• Table 1 for information on screening for arbovirus (Zik, dengue, chikungunya) infections in pregnancy. [17, 35] * There is no published data to support or refute use. Safety in pregnancy is based on clinical experience. [17] ** Loratadine is a FDA Catagory B medication and is used in pregnancy. -These repellants should be applied to exposed skin and over clothing (not under clothing), if using sunscreen apply sunscreen first then repellent. -Oil of lemon eucalyptus is often listed as an optional insect repellent but should be AVOIDED in pregnancy and breastfeeding [43] . The Environmental Protection Agency (EPA) has not evaluated natural insect repellents [44] .
• Avoidance of subsequent mosquito bites by following the above recommendations prevents transmission of the disease to others [17] . 
PREVENTION OF SEXUAL TRANSMISSION
